Critical stoichiometric ratio of CD4+ CD25+ FoxP3+ regulatory T cells and CD4+ CD25- responder T cells influence immunosuppression in patients with B-cell acute lymphoblastic leukaemia

Immunology

Volumn 142, Issue 1, 2014, Pages 124-139

  Bhattacharya, Kaushik ^a   Chandra, Sarmila ^b   Mandal, Chitra ^a  

^a INDIAN INSTITUTE OF CHEMICAL BIOLOGY   (India)

^b Park Clinic   (India)

Author keywords

B cell acute lymphoblastic leukaemia; FoxP3; Immunosuppression; Regulatory T cells; Responder T cells

Indexed keywords

ANTINEOPLASTIC AGENT; CD19 ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; INTERLEUKIN 10; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; B CELL LEUKEMIA; CANCER CHEMOTHERAPY; CANCER GROWTH; CD4+ CD25+ T LYMPHOCYTE; CHILD; COCULTURE; CONTROLLED STUDY; EX VIVO STUDY; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; GLYCOSYLATION; HELPER CELL; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; IMMUNOPHENOTYPING; LEUKEMIA REMISSION; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE PROLIFERATION; MAJOR CLINICAL STUDY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRESCHOOL CHILD; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SCHOOL CHILD; STOICHIOMETRY;

B-CELL ACUTE LYMPHOBLASTIC LEUKAEMIA; FOXP3; IMMUNOSUPPRESSION; REGULATORY T CELLS; RESPONDER T CELLS;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CASE-CONTROL STUDIES; CELL DIFFERENTIATION; CELLS, CULTURED; CHILD; CHILD, PRESCHOOL; COCULTURE TECHNIQUES; CYTOKINES; DISEASE PROGRESSION; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; IMMUNE TOLERANCE; INFANT; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; MALE; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; REMISSION INDUCTION; T-LYMPHOCYTES, REGULATORY; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84897974285     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/imm.12237     Document Type: Article

References (56)

1. + immunoregulatory T cells: central players in the arena of peripheral tolerance. Semin Immunol 2004; 16:81-8.
2. + regulatory T cells in autoimmunity: immunopathogenesis and therapeutic implications. Am J Pathol 2009; 174:1575-87.
3. + regulatory T cells conveying respiratory tolerance. J Immunol 2012; 189:1975-82.
4. Josefowicz SZ, Rudensky A. Control of regulatory T cell lineage commitment and maintenance. Immunity 2009; 30:616-25.
5. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor α-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995; 155:1151-64.
6. Sakaguchi S, Sakaguchi N. Regulatory T cells in immunologic self tolerance and autoimmune disease. Int Rev Immunol 2005; 24:211-26.
7. Chauhan SK, Saban DR, Lee HK, Dana R. Levels of Foxp3 in regulatory T cells reflect their functional status in transplantation. J Immunol 2009; 182:148-53.
8. Ahmadzadeh M, Felipe-Silva A, Heemskerk B, Powell DJ Jr, Wunderlich JR, Merino MJ, Rosenberg SA. FOXP3 expression accurately defines the population of intratumoral regulatory T cells that selectively accumulate in metastatic melanoma lesions. Blood 2008; 112:4953-60.
9. + Treg cells. J Exp Med 2006; 203:1701-11.
10. Dejaco C, Duftner C, Grubeck-Loebenstein B, Schirmer M. Imbalance of regulatory T cells in human autoimmune diseases. Immunology 2006; 117:289-300.
11. + regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 2004; 22:531-62.
12. + T cells inhibit both the induction and effector function of autoreactive T cells and represent a unique lineage of immunoregulatory cells. J Immunol 1998; 160:1212-8.
13. Curiel TJ. Tregs and rethinking cancer immunotherapy. J Clin Invest 2007; 117:1167-74.
14. Chen ML, Pittet MJ, Gorelik L, Flavell RA, Weissleder R, von Boehmer H, Khazaie K. Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-β signals in vivo. Proc Natl Acad Sci USA 2005; 102:419-24.
15. + helper T cell responses in cancer patients. Blood 2005; 106:1008-11.
16. + regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med 2003; 9:1144-50.
17. + regulatory T cells suppress lethal acute graft-versushost disease after allogeneic bone marrow transplantation. J Exp Med 2002; 196:389-99.
18. + regulatory T-cell levels in patients with melanoma. Clin Cancer Res 2003; 9:2551-9.
19. Marshall NA, Christie LE, Munro LR, Culligan DJ, Johnston PW, Barker RN, Vickers MA. Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma. Blood 2004; 103:1755-62.
20. + T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 2001; 61:4766-72.
21. Ichihara F, Kono K, Takahashi A, Kawaida H, Sugai H, Fujii H. Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers. Clin Cancer Res 2003; 9:4404-8.
22. Liyanage UK, Moore TT, Joo HG et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 2002; 169:2756-61.
23. Rodriguez-Pinto D, Navas A, Blanco VM et al. Regulatory T cells in the pathogenesis and healing of chronic human dermal leishmaniasis caused by Leishmania (Viannia) species. PLoS Negl Trop Dis 2012; 6:e1627.
24. + regulatory T cells attenuates LPS-induced systemic inflammatory responses and promotes survival in murine Escherichia coli infection. Shock 2013; 40:65-73.
25. Linet MS, Ries LA, Smith MA, Tarone RE, Devesa SS. Cancer surveillance series: recent trends in childhood cancer incidence and mortality in the United States. J Natl Cancer Inst 1999; 91:1051-8.
26. Gurney JG, Severson RK, Davis S, Robison LL. Incidence of cancer in children in the United States, sex, race, and 1-year age-specific rates by histologic type. Cancer 1995; 75:2186-95.
27. Pui CH. Acute lymphocytic leukemia. Pediatr Clin North Am 1997; 44:831-46.
28. Pui CH. Acute lymphocytic leukemia in children. Curr Opin Oncol 2000; 12:3-12.
29. hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood 2005; 106:2018-25.
30. lo regulatory T cells is associated to poor prognosis in patients with acute myeloid leukemia. Int J Cancer 2011; 129:1373-81.
31. Stasiak-Barmuta A, Luczyński W, Ilendo E, Krawczuk-Rybak M, Szymański M. Regulatory T cells in children with acute lymphoblastic leukaemia. Med Wieku Rozwoj 2009; 13:53-8.
32. + regulatory T cells in patients with acute lymphoblastic leukemia. Oncol Lett 2012; 3:421-4.
33. Basu S, Sarkar M, Mandal C. A single step purification of a sialic acid binding lectin (AchatininH) from Achatina fulica snail. Mol Cell Biochem 1986; 71:149-57.
34. Mandal C, Chowdhury M. The polyclonal activation of lymphocytes and T cell mitogenicity by a unique sialic-acid-binding lectin from the hemolymph of Achatina fulica snail. Immunopharmacology 1990; 20:63-72.
35. Sen G, Mandal C, Chowdhury M. Albumen gland of the snail Achatina fulica is the site for synthesis of AchatininH, a sialic acid binding lectin. Mol Cell Biochem 1992; 117:133-8.
36. Wilkins AL, Yang W, Yang JJ. Structural biology of the cell adhesion protein CD2: from molecular recognition to protein folding and design. Curr Protein Pept Sci 2003; 4:367-73.
37. Subrahmanyam G, Rudd CE, Schneider H. Association of T cell antigen CD7 with type II phosphatidylinositol-4 kinase, a key component in pathways of inositol phosphate turnover. Eur J Immunol 2003; 33:46-52.
38. Altin JG, Sloan EK. The role of CD45 and CD45-associated molecules in T cell activation. Immunol Cell Biol 1997; 75:430-45.
39. Raje NS, Vaidya SJ, Kapoor G, Pai SK, Nair CN, Kurkure PA, Magrath IT, Advani SH. Low incidence of CNS relapse with cranial radiotherapy and intrathecal methotrexate in acute lymphoblastic leukemia. Indian Pediatr 1996; 33:556-60.
40. Chowdhury S, Bandyopadhyay S, Mandal C, Chandra S, Mandal C. Flow-cytometric monitoring of disease-associated expression of 9-O-acetylated sialoglycoproteins in combination with known CD antigens, as an index for MRD in children with acute lymphoblastic leukaemia: a two-year longitudinal follow-up study. BMC Cancer 2008; 8:40.
41. Basu S, Mandal C, Allen AK. Chemical-modification studies of a unique sialic acid-binding lectin from the snail Achatina fulica. Involvement of tryptophan and histidine residues in biological activity. Biochem J 1988; 254:195-202.
42. Mandal C, Basu S, Mandal C. Physiochemical studies on achatinin H, a novel sialic acid-binding lectin. Biochem J 1989; 257:65-71.
43. Mandal C, Mandal C. Sialic acid binding lectins. Experientia 1990; 46:433-41.
44. Sen G, Chowdhury M, Mandal C. O-acetylated sialic acid as a distinct marker for differentiation between several leukemia erythrocytes. Mol Cell Biochem 1994; 136:65-70.
45. Mandal C, Sinha D, Sharma V, Bhattacharya DK. O-acetyl sialic acid binding lectin as a probe for detection of subtle change on cell surface induced during acute lymphoblastic leukemia (ALL) and its clinical application. Indian J Biochem Biophys 1997; 34:82-6.
46. Sinha D, Mandal C, Bhattacharya DK. Identification of 9-O acetyl sialoglycoconjugates (9-OAcSGs) as biomarkers in childhood acute lymphoblastic leukemia using a lectin, AchatininH, as a probe. Leukemia 1999; 13:119-25.
47. Biswas C, Sinha D, Mandal C. Investigation on interaction of Achatinin, a 9-O-acetyl sialic acid-binding lectin, with lipopolysaccharide in the innate immunity of Achatina fulica snails. Mol Immunol 2000; 37:745-54.
48. Pal S, Ghosh S, Bandyopadhyay S, Mandal C, Bandhyopadhyay S, Bhattacharya DK, Mandal C. Differential expression of 9-O-acetylated sialoglycoconjugates on leukemic blasts: a potential tool for long-term monitoring of children with acute lymphoblastic leukemia. Int J Cancer 2004; 111:270-7.
49. Bandyopadhyay S, Bhattacharyya A, Mallick A et al. Over-expressed IgG2 antibodies against O-acetylated sialoglycoconjugates incapable of proper effector functioning in childhood acute lymphoblastic leukemia. Int Immunol 2005; 17:177-91.
50. + regulatory T cells. J Immunol 2006; 177:896-904.
51. + Tregs: limiting collateral damage. J Clin Invest 2004; 114:1372-8.
52. Crimeen-Irwin B, Scalzo K, Gloster S, Mottram PL, Plebanski M. Failure of immune homeostasis - the consequences of under and over reactivity. Curr Drug Targets Immune Endocr Metabol Disord 2005; 5:413-22.
53. Sharma DC. Standard protocol helps improve ALL survival rates in India. Lancet Oncol 2002; 3:710.
54. Kan S, Hazama S, Maeda K, Inoue Y, Homma S, Koido S, Okamoto M, Oka M. Suppressive effects of cyclophosphamide and gemcitabine on regulatory T-cell induction in vitro. Anticancer Res 2012; 32:5363-9.
55. + regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol 2004; 34:336-44.
56. + regulatory T cell activity and enhances active immunotherapy against BCR-ABL-tumors. J Immunol 2008; 181:6955-63.